Navigation Links
HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
Date:8/4/2011

FRAMINGHAM, Mass. and SYDNEY, Aug. 4, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenues of $20.4 million for the second quarter ended June 30, 2011.  This represents a 109 percent increase from $9.8 million in revenues for the same period of 2010.  For the six months ended June 30, 2011, the Company generated revenues of $38.4 million, compared to $20.5 million in the first half of 2010.

"During the second quarter, we generated global sales for the HeartWare® Ventricular Assist System of 226 units, up from 207 units in the first quarter of 2011, and up from 116 units in the second quarter of 2010.  In international markets, we are fortunate to have the strong support of our 64 customers in 20 countries, with 152 pumps sold to customers outside of the U.S.," stated Doug Godshall, President and Chief Executive Officer.  "The international markets accounted for 69 percent, or approximately $14.1 million, of our 2011 second quarter revenues, up from $7.9 million in the second quarter of 2010."

"In the U.S., where second quarter revenues more than tripled to $6.3 million compared to $1.9 million in the second quarter of 2010, we now have 47 of the planned 50 U.S. sites approved for implantation in our 450-patient destination therapy study, and 189 patients have been randomized and enrolled," added Mr. Godshall.  "In the second quarter, enrollment in our destination therapy study climbed nearly 50 percent from first quarter levels, from 43 to 63 patients. Enrollment in the 94-patient Continued Access Protocol (CAP) allotment under our bridge-to-transplant clinical study decreased from 29 patients in the first quarter 2011 to 22 patients enrolled i
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Hill-Rom Holdings, Inc. (NYSE: HRC ) will release ... 2011.  The company will host a webcast the following morning ... Earnings Release:   Hill-Rom,s Fiscal 2011 Third Quarter ... be issued to the public after the close of the ...
... 2011 U.S. Senators Jerry Moran ... established the first-ever Senate Community Pharmacy Caucus, an effort ... (NCPA). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO) The ... pharmacy issues while serving as a clearinghouse of ideas ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 Third Quarter Earnings Webcast 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 3
(Date:4/16/2014)... , While it is well known that fertility treatments ... and that multiples are at elevated risk of premature ... in Fertility and Sterility . The ... can reduce the odds of multiple births and prematurity, ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found a ... about 1.5 million people a year. The researchers say they now ... has been in use for more than 50 years even ... is to the microbes it attacks. , A report ...
(Date:4/14/2014)... advances have been made in chemotherapy over the past ... healthy tissues continues to be a major challenge. ... delivery, including the use of nanocarriers, or capsules, that ... in the body. , The catch? These carriers are ...
(Date:4/14/2014)... American Associations for Dental Research (IADR/AADR) have published a ... and Craniofacial Manifestations." The complete review by researchers Sunday ... Collins, Brian L. Foster, Rachel I. Gafni, Janice S. ... Timothy Wright is published in the OnlineFirst portion of ...
(Date:4/14/2014)... treatment decisions leaves cancer patients feeling more satisfied with ... the experience, researchers from the Perelman School of ... the journal Cancer . , In a study ... MD , an associate professor in the department in ...
Breaking Medicine News(10 mins):Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... with CyberKnife Radiosurgery Worldwide, SUNNYVALE, Calif., Nov. ... global leader in the field of radiosurgery,today announced ... to treat more than 4,000 lung cancer patients ... patients in total have been treated,with CyberKnife radiosurgery ...
... 25% of all,cancers are due to genetic factors, patients that ... on the lookout for the early warning signs of,cancer. This ... from,both a medical and psychological prospective. Cancer does run ... Today, suggests it is misleading to think of cancer as ...
... (NYSE: SGP ) today announced that it ... Commission (FTC) regarding its,planned acquisition of Organon BioSciences ... 2007. Organon BioSciences is comprised mainly of ... health business. It also,includes Nobilon, the human vaccine ...
... of Georgia Drug Agency Approves Protocol for New Clinical ... of Bavituximab in Combination with ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company ... C virus (HCV) infection, today announced that its Phase ...
... following is being,issued by the National Council on Disability:, ... to December 1, 2007., WHERE:, Hyatt Regency Boston ... November 29, 2007, 8:30 a.m. - 10:00 a.m. ... Vaughn -- Introduction of Council Members, NCD staff and ...
... 16 21st Services has created its,first Medical Advisory ... an innovative approach in the life settlement industry. ... the sophistication,of its underwriting model and its life expectancy ... up of physicians from,across the country who are experts ...
Cached Medicine News:Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 2Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 3Health News:Genetics and Risk, This Week on Your Cancer Today(TM) 2Health News:Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V. 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 2Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 3Health News:In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk 2
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... the osteotomy staples is quite similar to the type ... inner position of the anti recoil contours and the ... There are 3 kinds of staples: 1. Straight ... staples can have 3 different widths: 20mm, 26 mm ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
Medicine Products: